Planning Alternatives’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$903K Buy
982
+95
+11% +$96.3K 0.12% 46
2025
Q4
$953K Buy
887
+296
+50% +$283K 0.12% 44
2025
Q3
$451K Sell
591
-141
-19% -$105K 0.06% 57
2025
Q2
$571K Sell
732
-148
-17% -$115K 0.08% 48
2025
Q1
$727K Buy
880
+315
+56% +$262K 0.11% 35
2024
Q4
$436K Buy
565
+6
+1% +$4.97K 0.07% 41
2024
Q3
$495K Buy
559
+16
+3% +$14.4K 0.08% 38
2024
Q2
$492K Buy
543
+96
+21% +$76.8K 0.08% 39
2024
Q1
$348K Buy
447
+29
+7% +$20.6K 0.06% 39
2023
Q4
$244K Buy
418
+3
+0.7% +$1.75K 0.04% 44
2023
Q3
$223K Buy
+415
New +$214K 0.04% 43

Other funds holding LLY

Planning Alternatives's LLY Position: Q1 2026 in Review

Planning Alternatives increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $96.3K and bringing the position to 982 shares worth $903K. The position accounts for 0.12% of the portfolio, ranked #46.

Planning Alternatives first reported a position in LLY in Q3 2023 and has held it in 11 quarters since. The position peaked at $953K in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Planning Alternatives held 982 shares of Eli Lilly worth $903K as of Q1 2026.
  • Planning Alternatives bought 95 Eli Lilly shares in Q1 2026, an estimated $96.3K.
  • Eli Lilly made up 0.12% of Planning Alternatives's portfolio in Q1 2026, its #46 holding.
  • Planning Alternatives first reported a position in Eli Lilly in Q3 2023 and has held it in 11 quarters since.
  • Planning Alternatives's Eli Lilly position peaked at $953K in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Planning Alternatives's 13F filing for Q1 2026, filed 7 May 2026.